Treating NonAlcoholic Fatty Liver Disease and NonAlcoholic SteatoHepatitis is a possibility.

Corliva™ is in development to be a Best-in-Class, orally administered adjunct to Type2 Diabetes management indicated to treat NAFLD and NASH with no worsening of Fibrosis (Stage F0 through F2).
Between 30%-40% of adults in the US have NAFLD and about 3%-12% percent of adults have NASH, a progressive form of NAFLD that can lead to cardiovascular disease, cirrhosis and liver-related mortality.  From 40% - 80% of those with Type2 Diabetes have NAFLD or NASH.